跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD7-CAR-T
首页
药物
CD7-CAR-T
CD7-CAR-T
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
USE OF CD2/5/7 KNOCK-OUT ANTI-CD2/5/7 CHIMERIC ANTIGEN RECEPTOR T CELLS AGAINST T CELL LYMPHOMAS AND LEUKEMIAS
EP 3898692 A4
申请人: UNIV PENNSYLVANIA
优先权: 2018
CN
EP
US
WO
10 件公开
ANTI-CD7 NANOBODY, AND DERIVATIVE THEREOF AND USE THEREOF IN TUMOR THERAPY
EP 4501962 A4
申请人: HEBEI SENLANG BIOTECHNOLOGY CO LTD
优先权: 2022
CN
EP
US
WO
7 件公开
MODIFIED INVARIANT NATURAL KILLER T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF
EP 4482501 A4
申请人: TINKESO THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
4 件公开
ANTIBODY TARGETING HUMAN CD7 OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF
EP 4748858 A1
申请人: NANJING PROBIO BIOTECH CO LTD
优先权: 2023
CN
EP
WO
4 件公开
CD7-TARGETED ENGINEERED IMMUNE CELL, CHIMERIC ANTIGEN RECEPTOR, CD7 BLOCKING MOLECULE AND USE THEREOF
US 20240075143 A1
申请人: SHANGHAI YAKE BIOTECHNOLOGY LTD
优先权: 2021
CN
US
4 件公开
ENGINEERED IMMUNE CELL WITH CD7 GENE KNOCK-OUT AND USE THEREOF
EP 4502150 A1
申请人: NANJING BIOHENG BIOTECH CO LTD
优先权: 2022
CN
EP
US
3 件公开
CD7-CAR-T cell and preparation and application thereof
CN 115925976 A
申请人: PERSONGEN BIOMEDICINE SUZHOU CO LTD
优先权: 2019
CN
3 件公开
PREPARATION METHOD AND APPLICATION OF CD7-CAR-T CELLS
US 20240016842 A1
申请人: PERSONGEN BIOTHERAPEUTICS SUZHOU CO LTD
优先权: 2020
CN
US
2 件公开
CD7-BASED HUMANIZED CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
US 20250222026 A1
申请人: BEIJING MEIKANG GENO IMMUNE BIOTECHNOLOGY CO LTD
优先权: 2021
CN
US
2 件公开
FULLY HUMANIZED CHIMERIC ANTIGEN RECEPTOR (CAR) FOR CD5 AND CD7 DUAL TARGETS, AND USE THEREOF
WO 2023011651 A1
申请人: SHANGHAI IASO BIOTECHNOLOGY CO LTD
优先权: 2021
CN
WO
2 件公开
第 1 / 5 页
上一页
下一页
药物
反馈